

Stephen W Duffy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9527830/publications.pdf>

Version: 2024-02-01

264
papers

18,893
citations

16791

66
h-index

15253

130
g-index

273
all docs

273
docs citations

273
times ranked

14382
citing authors

#	ARTICLE	IF	CITATIONS
1	A case-control study to evaluate the impact of the breast screening programme on breast cancer incidence in England. <i>Cancer Medicine</i> , 2023, 12, 1878-1887.	1.3	8
2	Higher Adenoma Detection Rates at Screening Associated With Lower Long-Term Colorectal Cancer Incidence and Mortality. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e148-e167.	2.4	16
3	Selection of eligible participants for screening for lung cancer using primary care data. <i>Thorax</i> , 2022, 77, 882-890.	2.7	13
4	Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC). <i>British Journal of Cancer</i> , 2022, 126, 673-688.	2.9	22
5	All-cause mortality in multi-cancer screening trials. <i>Journal of Medical Screening</i> , 2022, 29, 1-2.	1.1	0
6	Quantifying the duration of the preclinical detectable phase in cancer screening: a systematic review. <i>Epidemiology and Health</i> , 2022, 44, e2022008.	0.8	3
7	Modeling Multicancer Screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 3-4.	1.1	0
8	A Randomized Trial Comparing Breast Cancer Incidence and Interval Cancers after Tomosynthesis Plus Mammography versus Mammography Alone. <i>Radiology</i> , 2022, 303, 256-266.	3.6	29
9	The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation. <i>British Journal of Cancer</i> , 2022, 126, 1355-1361.	2.9	28
10	Recovery of the breast screening programme following pandemic-related delays: Should we focus on round length or uptake?. <i>Journal of Medical Screening</i> , 2022, , 096914132110664.	1.1	1
11	A new approach to breast cancer terminology based on the anatomic site of tumour origin: The importance of radiologic imaging biomarkers. <i>European Journal of Radiology</i> , 2022, 149, 110189.	1.2	17
12	Developing Reporting Guidelines for Social Media Research (RESOME) by Using a Modified Delphi Method: Protocol for Guideline Development. <i>JMIR Research Protocols</i> , 2022, 11, e31739.	0.5	1
13	Problems With the Canadian National Breast Screening Studies. <i>Journal of Breast Imaging</i> , 2022, 4, 120-121.	0.5	3
14	Post-polypectomy surveillance interval and advanced neoplasia detection rates: a multicenter, retrospective cohort study. <i>Endoscopy</i> , 2022, 54, 948-958.	1.0	5
15	Breast cancers originating from the terminal ductal lobular units: In situ and invasive acinar adenocarcinoma of the breast, AAB. <i>European Journal of Radiology</i> , 2022, 152, 110323.	1.2	10
16	The role of computer-assisted radiographer reporting in lung cancer screening programmes. <i>European Radiology</i> , 2022, , 1.	2.3	0
17	Benefit of biennial faecal occult blood screening on colorectal cancer in England: A population-based case-control study. <i>Journal of the National Cancer Institute</i> , 2022, , .	3.0	1
18	Colonoscopy surveillance following adenoma removal to reduce the risk of colorectal cancer: a retrospective cohort study. <i>Health Technology Assessment</i> , 2022, 26, 1-156.	1.3	3

#	ARTICLE	IF	CITATIONS
19	Imaging biomarkers of breast cancers originating from the major lactiferous ducts: Ductal adenocarcinoma of the breast, DAB. <i>European Journal of Radiology</i> , 2022, 154, 110394.	1.2	7
20	Early detection of breast cancer rectifies inequality of breast cancer outcomes. <i>Journal of Medical Screening</i> , 2021, 28, 34-38.	1.1	13
21	A case-control study to evaluate the impact of the breast screening programme on mortality in England. <i>British Journal of Cancer</i> , 2021, 124, 736-743.	2.9	14
22	Liverpool Lung Project lung cancer risk stratification model: calibration and prospective validation. <i>Thorax</i> , 2021, 76, 161-168.	2.7	27
23	Heterogeneity in colorectal cancer incidence among people recommended 3-yearly surveillance post-polypectomy: a validation study. <i>Endoscopy</i> , 2021, 53, 402-410.	1.0	2
24	Retrospective comparison between single reading plus an artificial intelligence algorithm and two-view digital tomosynthesis with double reading in breast screening. <i>Journal of Medical Screening</i> , 2021, 28, 365-368.	1.1	6
25	P22â€¦Impact of adenoma detection rates at flexible sigmoidoscopy on long-term colorectal cancer incidence and mortality. , 2021, , .		0
26	Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative. <i>British Journal of Cancer</i> , 2021, 124, 1503-1512.	2.9	24
27	Detection of involved margins in breast specimens with X-ray phase-contrast computed tomography. <i>Scientific Reports</i> , 2021, 11, 3663.	1.6	22
28	Including a general practice endorsement letter with the testing kit in the Bowel Cancer Screening Programme: Results of a cluster randomised trial. <i>Journal of Medical Screening</i> , 2021, 28, 096914132199748.	1.1	0
29	Benefits and harms of breast cancer mammography screening for women at average risk of breast cancer: A systematic review for the European Commission Initiative on Breast Cancer. <i>Journal of Medical Screening</i> , 2021, 28, 389-404.	1.1	44
30	Artificial Intelligence Techniques That May Be Applied to Primary Care Data to Facilitate Earlier Diagnosis of Cancer: Systematic Review. <i>Journal of Medical Internet Research</i> , 2021, 23, e23483.	2.1	26
31	Colorectal cancer risk following polypectomy in a multicentre, retrospective, cohort study: an evaluation of the 2020 UK post-polypectomy surveillance guidelines. <i>Gut</i> , 2021, 70, 2307-2320.	6.1	18
32	Impact of changing from a guaiac faecal occult blood test to a faecal immunochemical test in a national screening programme: Results from a pilot study within the national bowel cancer screening programme in England. <i>Journal of Medical Screening</i> , 2021, 28, 096914132110133.	1.1	2
33	Quantitative breast density analysis to predict interval and node-positive cancers in pursuit of improved screening protocols: a caseâ€“control study. <i>British Journal of Cancer</i> , 2021, 125, 884-892.	2.9	7
34	Beneficial Effect of Consecutive Screening Mammography Examinations on Mortality from Breast Cancer: A Prospective Study. <i>Radiology</i> , 2021, 299, 541-547.	3.6	66
35	Psychological Targets for Lung Cancer Screening Uptake: A Prospective Longitudinal Cohort Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2016-2028.	0.5	15
36	Mammography Screening and Research Evidence: The Swedish Contribution. <i>Journal of Breast Imaging</i> , 2021, 3, 637-644.	0.5	1

#	ARTICLE	IF	CITATIONS
37	Analysis of the baseline performance of five UK lung cancer screening programmes. <i>Lung Cancer</i> , 2021, 161, 136-140.	0.9	29
38	Targeted encouragement of GP consultations for possible cancer symptoms: a randomised controlled trial. <i>British Journal of General Practice</i> , 2021, 71, e339-e346.	0.7	6
39	Faecal immunochemical testing in bowel cancer screening: Estimating outcomes for different diagnostic policies. <i>Journal of Medical Screening</i> , 2021, 28, 277-285.	1.1	5
40	Concurrent participation in screening for cervical, breast, and bowel cancer in England. <i>Journal of Medical Screening</i> , 2020, 27, 9-17.	1.1	14
41	Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients. <i>British Journal of Cancer</i> , 2020, 122, 692-696.	2.9	32
42	Lung Screen Uptake Trial (LSUT): Randomized Controlled Clinical Trial Testing Targeted Invitation Materials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 965-975.	2.5	77
43	Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems. <i>Cancers</i> , 2020, 12, 1929.	1.7	49
44	First results from five multidisciplinary diagnostic centre (MDC) projects for non-specific but concerning symptoms, possibly indicative of cancer. <i>British Journal of Cancer</i> , 2020, 123, 722-729.	2.9	41
45	Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines. <i>Annals of Internal Medicine</i> , 2020, 172, 46.	2.0	157
46	Lung Screen Uptake Trial: results from a single lung cancer screening round. <i>Thorax</i> , 2020, 75, 908-912.	2.7	13
47	Online patient simulation training to improve clinical reasoning: a feasibility randomised controlled trial. <i>BMC Medical Education</i> , 2020, 20, 245.	1.0	24
48	Precision Science on Incidence and Progression of Early-Detected Small Breast Invasive Cancers by Mammographic Features. <i>Cancers</i> , 2020, 12, 1855.	1.7	2
49	Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. <i>Lancet Oncology, The</i> , 2020, 21, 1165-1172.	5.1	110
50	The Evaluation of Cancer Screening. <i>Medical Clinics of North America</i> , 2020, 104, 939-953.	1.1	8
51	Weekly COVID-19 testing with household quarantine and contact tracing is feasible and would probably end the epidemic. <i>Royal Society Open Science</i> , 2020, 7, 200915.	1.1	35
52	Use of a GP-endorsed non-participant reminder letter to promote uptake of bowel scope screening: A randomised controlled trial in a hard-to-reach population. <i>Preventive Medicine</i> , 2020, 141, 106268.	1.6	1
53	Mammography screening for breast cancer—the UK Age trial — Authors' reply. <i>Lancet Oncology, The</i> , 2020, 21, e510.	5.1	2
54	Mammography screening reduces rates of advanced and fatal breast cancers: Results in 549,091 women. <i>Cancer</i> , 2020, 126, 2971-2979.	2.0	175

#	ARTICLE	IF	CITATIONS
55	What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420). <i>BMC Cancer</i> , 2020, 20, 570.	1.1	37
56	Prevalence, Symptom Burden, and Underdiagnosis of Chronic Obstructive Pulmonary Disease in a Lung Cancer Screening Cohort. <i>Annals of the American Thoracic Society</i> , 2020, 17, 869-878.	1.5	41
57	Errors in determination of net survival: cause-specific and relative survival settings. <i>British Journal of Cancer</i> , 2020, 122, 1094-1101.	2.9	19
58	Long-term colorectal cancer incidence after adenoma removal and the effects of surveillance on incidence: a multicentre, retrospective, cohort study. <i>Gut</i> , 2020, 69, 1645-1658.	6.1	50
59	Mortality Reduction with Low-Dose CT Screening for Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 572-573.	13.9	43
60	Worldwide Review and Meta-Analysis of Cohort Studies Measuring the Effect of Mammography Screening Programmes on Incidence-Based Breast Cancer Mortality. <i>Cancers</i> , 2020, 12, 976.	1.7	72
61	Radiological audit of interval breast cancers: Estimation of tumour growth rates. <i>Breast</i> , 2020, 51, 114-119.	0.9	14
62	Psychological outcomes of low-dose CT lung cancer screening in a multisite demonstration screening pilot: the Lung Screen Uptake Trial (LSUT). <i>Thorax</i> , 2020, 75, 1065-1073.	2.7	14
63	A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003489.	3.9	33
64	Calculating, Using and Improving Individual Breast Cancer Risk Estimates. , 2020, , 309-324.		1
65	Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-24.	1.3	23
66	Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme. <i>Lung Cancer</i> , 2019, 134, 66-71.	0.9	40
67	Impact of choice of volumetry software and nodule management guidelines on recall rates in lung cancer screening. <i>European Journal of Radiology</i> , 2019, 120, 108646.	1.2	15
68	A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1718.	3.4	91
69	Long-term excess risk of breast cancer after a single breast density measurement. <i>European Journal of Cancer</i> , 2019, 117, 41-47.	1.3	5
70	Imaging Biomarkers as Predictors for Breast Cancer Death. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	0.6	8
71	Probability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial. <i>Thorax</i> , 2019, 74, 761-767.	2.7	28
72	Towards evidence-based follow-up intervals for breast cancer survivors: Estimates of the preclinical detectable phase of contralateral second breast cancer. <i>Breast</i> , 2019, 45, 70-74.	0.9	0

#	ARTICLE	IF	CITATIONS
73	Test sensitivity of mammography and mean sojourn time over 40 years of breast cancer screening in Nijmegen (The Netherlands). <i>Journal of Medical Screening</i> , 2019, 26, 147-153.	1.1	13
74	“They say it’s more aggressive in black women” Biosociality, breast cancer, and becoming a population at risk. <i>Transactions of the Institute of British Geographers</i> , 2019, 44, 509-523.	1.8	4
75	Methods for Development of the European Commission Initiative on Breast Cancer Guidelines. <i>Annals of Internal Medicine</i> , 2019, 171, 273.	2.0	39
76	Impact of a Lung Cancer Screening Information Film on Informed Decision-making: A Randomized Trial. <i>Annals of the American Thoracic Society</i> , 2019, 16, 744-751.	1.5	23
77	Evaluation of cardiovascular risk in a lung cancer screening cohort. <i>Thorax</i> , 2019, 74, 1140-1146.	2.7	50
78	Risk stratification in breast screening: A word of caution. <i>Journal of Medical Screening</i> , 2019, 26, 57-58.	1.1	1
79	The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. <i>Cancer</i> , 2019, 125, 515-523.	2.0	151
80	Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study. <i>Gut</i> , 2019, 68, 1642-1652.	6.1	53
81	Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study. <i>Health Technology Assessment</i> , 2019, 23, 1-84.	1.3	91
82	What Proportion of People Who Try One Cigarette Become Daily Smokers? A Meta-Analysis of Representative Surveys. <i>Nicotine and Tobacco Research</i> , 2018, 20, 1427-1433.	1.4	33
83	Low-dose CT for lung cancer screening – Authors’ reply. <i>Lancet Oncology</i> , The, 2018, 19, e135-e136.	5.1	3
84	Association between Screening Mammography Recall Rate and Interval Cancers in the UK Breast Cancer Service Screening Program: A Cohort Study. <i>Radiology</i> , 2018, 288, 47-54.	3.6	21
85	The impact of trained radiographers as concurrent readers on performance and reading time of experienced radiologists in the UK Lung Cancer Screening (UKLS) trial. <i>European Radiology</i> , 2018, 28, 226-234.	2.3	21
86	Screening organization and recall rate in a regional breast screening programme. <i>Journal of Medical Screening</i> , 2018, 25, 55-56.	1.1	1
87	Mammographic density and breast cancer risk in breast screening assessment cases and women with a family history of breast cancer. <i>European Journal of Cancer</i> , 2018, 88, 48-56.	1.3	53
88	Effect of Mammography Screening on Mortality by Histological Grade. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 154-157.	1.1	28
89	Patient selection for future lung cancer computed tomography screening programmes: lessons learnt post National Lung Cancer Screening Trial. <i>Translational Lung Cancer Research</i> , 2018, 7, S114-S116.	1.3	1
90	OTU-029...Faecal immunochemical tests (FIT) for surveillance after screening and polypectomy: an accuracy and efficiency study. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
91	Association of symptoms and interval breast cancers in the mammography-screening programme: population-based matched cohort study. <i>British Journal of Cancer</i> , 2018, 119, 1428-1435.	2.9	4
92	Reply to "Comment on "Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis": <i>British Journal of Cancer</i> , 2018, 119, 1444-1444.	2.9	0
93	The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review. <i>BMC Cancer</i> , 2018, 18, 860.	1.1	42
94	Lung cancer CT screening: are we ready to consider screening biennially in a subgroup of low-risk individuals?. <i>Thorax</i> , 2018, 73, 1006-1007.	2.7	6
95	Trends in lung cancer emergency presentation in England, 2006"2013: is there a pattern by general practice?. <i>BMC Cancer</i> , 2018, 18, 615.	1.1	4
96	Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis. <i>British Journal of Cancer</i> , 2018, 118, 1559-1570.	2.9	92
97	Use of a GP-endorsed 12 months' reminder letter to promote uptake of bowel scope screening: protocol for a randomised controlled trial in a hard-to-reach population. <i>BMJ Open</i> , 2018, 8, e022263.	0.8	2
98	Evaluation issues in the Swedish Two-County Trial of breast cancer screening: An historical review. <i>Journal of Medical Screening</i> , 2017, 24, 27-33.	1.1	11
99	Initiators and promoters for the occurrence of screen-detected breast cancer and the progression to clinically-detected interval breast cancer. <i>Journal of Epidemiology</i> , 2017, 27, 98-106.	1.1	8
100	Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. <i>Lancet</i> , The, 2017, 389, 1299-1311.	6.3	277
101	Optimum low dose CT screening interval for lung cancer: the answer from NELSON?. <i>Thorax</i> , 2017, 72, 6-7.	2.7	10
102	Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study. <i>Lancet Oncology</i> , The, 2017, 18, 823-834.	5.1	169
103	Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 972-980.	5.1	15
104	GP participation in increasing uptake in a national bowel cancer screening programme: the PEARL project. <i>British Journal of Cancer</i> , 2017, 116, 1551-1557.	2.9	27
105	Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality. <i>Evidence-Based Medicine</i> , 2017, 22, 76-76.	0.6	2
106	Does Reader Performance with Digital Breast Tomosynthesis Vary according to Experience with Two-dimensional Mammography?. <i>Radiology</i> , 2017, 283, 371-380.	3.6	24
107	A randomised trial of screening with digital breast tomosynthesis plus conventional digital 2D mammography versus 2D mammography alone in younger higher risk women. <i>European Journal of Radiology</i> , 2017, 94, 133-139.	1.2	8
108	Colorectal adenomas, surveillance, and cancer " Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e428.	5.1	1

#	ARTICLE	IF	CITATIONS
109	Fear, family and the placing of emotion: Black women's responses to a breast cancer awareness intervention. <i>Social Science and Medicine</i> , 2017, 195, 90-96.	1.8	7
110	European position statement on lung cancer screening. <i>Lancet Oncology</i> , The, 2017, 18, e754-e766.	5.1	428
111	Rapid review of evaluation of interventions to improve participation in cancer screening services. <i>Journal of Medical Screening</i> , 2017, 24, 127-145.	1.1	100
112	Reducing the socioeconomic gradient in uptake of the NHS bowel cancer screening Programme using a simplified supplementary information leaflet: a cluster-randomised trial. <i>BMC Cancer</i> , 2017, 17, 543.	1.1	8
113	The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations. <i>Health Technology Assessment</i> , 2017, 21, 1-536.	1.3	23
114	Testing innovative strategies to reduce the social gradient in the uptake of bowel cancer screening: a programme of four qualitatively enhanced randomised controlled trials. <i>Programme Grants for Applied Research</i> , 2017, 5, 1-302.	0.4	1
115	Reducing the Social Gradient in Uptake of the NHS Colorectal Cancer Screening Programme Using a Narrative-Based Information Leaflet: A Cluster-Randomised Trial. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-10.	0.7	10
116	Explaining the Better Prognosis of Screening-Exposed Breast Cancers: Influence of Tumor Characteristics and Treatment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 479-487.	1.1	10
117	Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial. <i>Thorax</i> , 2016, 71, 996-1005.	2.7	74
118	Incorporating epistasis interaction of genetic susceptibility single nucleotide polymorphisms in a lung cancer risk prediction model. <i>International Journal of Oncology</i> , 2016, 49, 361-370.	1.4	20
119	Impact of Screening on Breast Cancer Mortalityâ€”Response. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 873-873.	1.1	0
120	Impact of Screening on Breast Cancer Mortality: The UK Program 20 Years On. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 455-462.	1.1	79
121	Implementation planning for lung cancer screening: five major challenges. <i>Lancet Respiratory Medicine</i> , 2016, 4, 685-687.	5.2	13
122	Comparing the performance of trained radiographers against experienced radiologists in the UK lung cancer screening (UKLS) trial. <i>British Journal of Radiology</i> , 2016, 89, 20160301.	1.0	14
123	Updated results of the Gothenburg Trial of Mammographic Screening. <i>Cancer</i> , 2016, 122, 1832-1835.	2.0	24
124	A national cluster-randomised controlled trial to examine the effect of enhanced reminders on the socioeconomic gradient in uptake in bowel cancer screening. <i>British Journal of Cancer</i> , 2016, 115, 1479-1486.	2.9	10
125	Is cancer survival associated with cancer symptom awareness and barriers to seeking medical help in England? An ecological study. <i>British Journal of Cancer</i> , 2016, 115, 876-886.	2.9	51
126	Evaluating a DVD promoting breast cancer awareness among black women aged 25â€”50â€”years in East London. <i>Journal of Epidemiology and Community Health</i> , 2016, 70, 678-682.	2.0	4

#	ARTICLE	IF	CITATIONS
127	Ovarian cancer screening: UKCTOCS trial. <i>Lancet, The</i> , 2016, 387, 2602.	6.3	8
128	DCIS and invasive interval breast cancer – Author's reply. <i>Lancet Oncology, The</i> , 2016, 17, e88-e89.	5.1	1
129	Response to Hersch etÂal.. <i>Journal of Medical Screening</i> , 2016, 23, 56-56.	1.1	1
130	Estimation of overdiagnosis using short-term trends and lead time estimates uncontaminated by overdiagnosed cases: Results from the Norwegian Breast Screening Programme. <i>Journal of Medical Screening</i> , 2016, 23, 192-202.	1.1	20
131	Effectiveness of timed and non-timed second appointments in improving uptake in breast cancer screening. <i>Journal of Medical Screening</i> , 2016, 23, 160-163.	1.1	12
132	The Lung Screen Uptake Trial (LSUT): protocol for a randomised controlled demonstration lung cancer screening pilot testing a targeted invitation strategy for high risk and –hard-to-reach–™ patients. <i>BMC Cancer</i> , 2016, 16, 281.	1.1	50
133	A randomised trial of the effect of postal reminders on attendance for breast screening. <i>British Journal of Cancer</i> , 2016, 114, 171-176.	2.9	14
134	Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. <i>Lancet Oncology, The</i> , 2016, 17, 109-114.	5.1	108
135	CT screening for lung cancer: Is the evidence strong enough?. <i>Lung Cancer</i> , 2016, 91, 29-35.	0.9	34
136	Lung cancer CT screening: is annual screening necessary?. <i>Lancet Oncology, The</i> , 2016, 17, 543-544.	5.1	14
137	Socioeconomic inequalities in breast and cervical screening coverage in England: are we closing the gap?. <i>Journal of Medical Screening</i> , 2016, 23, 98-103.	1.1	69
138	UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. <i>Thorax</i> , 2016, 71, 161-170.	2.7	263
139	Effects of evidence-based strategies to reduce the socioeconomic gradient of uptake in the English NHS Bowel Cancer Screening Programme (ASCEND): four cluster-randomised controlled trials. <i>Lancet, The</i> , 2016, 387, 751-759.	6.3	120
140	Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening. <i>British Journal of Cancer</i> , 2016, 114, 321-326.	2.9	35
141	The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-146.	1.3	204
142	Overdiagnosis associated with breast cancer screening: A simulation study to compare lead-time adjustment methods. <i>Cancer Epidemiology</i> , 2015, 39, 1128-1135.	0.8	11
143	Response to Miller etÂal.. <i>Breast Journal</i> , 2015, 21, 459-461.	0.4	2
144	Estimates of over-diagnosis of breast cancer due to population-based mammography screening in South Australia after adjustment for lead time effects. <i>Journal of Medical Screening</i> , 2015, 22, 127-135.	1.1	21

#	ARTICLE	IF	CITATIONS
145	Case-control Studies on the Effectiveness of Breast Cancer Screening. <i>Epidemiology</i> , 2015, 26, 590-596.	1.2	10
146	Variation in cervical and breast cancer screening coverage in England: a cross-sectional analysis to characterise districts with atypical behaviour. <i>BMJ Open</i> , 2015, 5, e007735.	0.8	32
147	Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. <i>BMJ Open</i> , 2015, 5, e008254.	0.8	136
148	Assessing Improvement in Detection of Breast Cancer with Three-dimensional Automated Breast US in Women with Dense Breast Tissue: The Somolnsight Study. <i>Radiology</i> , 2015, 274, 663-673.	3.6	274
149	Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1123-1132.	5.1	159
150	Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 3512-3521.	3.2	161
151	Accuracy of Digital Breast Tomosynthesis for Depicting Breast Cancer Subgroups in a UK Retrospective Reading Study (TOMMY Trial). <i>Radiology</i> , 2015, 277, 697-706.	3.6	149
152	Impact of comorbidity on lung cancer mortality - a report from the Liverpool Lung Project. <i>Oncology Letters</i> , 2015, 9, 1902-1906.	0.8	15
153	LLPi: Liverpool Lung Project Risk Prediction Model for Lung Cancer Incidence. <i>Cancer Prevention Research</i> , 2015, 8, 570-575.	0.7	60
154	A note on the design of cancer screening trials. <i>Journal of Medical Screening</i> , 2015, 22, 65-68.	1.1	17
155	Likely effect of adding flexible sigmoidoscopy to the English NHS Bowel Cancer Screening Programme: impact on colorectal cancer cases and deaths. <i>British Journal of Cancer</i> , 2015, 113, 142-149.	2.9	24
156	Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPEC. <i>British Journal of Cancer</i> , 2015, 113, 1086-1093.	2.9	32
157	Informed Decision-Making and Breast Cancer Screening. <i>Journal of Medical Screening</i> , 2015, 22, 165-167.	1.1	13
158	Systematic review of the breast cancer screening trials is error-ridden. <i>Journal of the Royal Society of Medicine</i> , 2015, 108, 430-431.	1.1	1
159	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. <i>Genetics in Medicine</i> , 2015, 17, 789-795.	1.1	87
160	Insights from the Breast Cancer Screening Trials: How Screening Affects the Natural History of Breast Cancer and Implications for Evaluating Service Screening Programs. <i>Breast Journal</i> , 2015, 21, 13-20.	0.4	134
161	A case-control study to assess the impact of mammographic density on breast cancer risk in women aged 40-49 at intermediate familial risk. <i>International Journal of Cancer</i> , 2015, 136, 2378-2387.	2.3	11
162	The TOMMY trial: a comparison of TOMosynthesis with digital MammographY in the UK NHS Breast Screening Programme - a multicentre retrospective reading study comparing the diagnostic performance of digital breast tomosynthesis and digital mammography with digital mammography alone. <i>Health Technology Assessment</i> , 2015, 19, 1-136.	1.3	146

#	ARTICLE	IF	CITATIONS
163	Factors associated with dropout in a lung cancer high-risk cohort - the Liverpool lung project. <i>International Journal of Oncology</i> , 2014, 44, 2146-2152.	1.4	6
164	Translation of research results to simple estimates of the likely effect of a lung cancer screening programme in the United Kingdom. <i>British Journal of Cancer</i> , 2014, 110, 1834-1840.	2.9	32
165	Reduction in interval cancer rates following the introduction of two-view mammography in the UK breast screening programme. <i>British Journal of Cancer</i> , 2014, 110, 560-564.	2.9	16
166	Evaluation of a service intervention to improve awareness and uptake of bowel cancer screening in ethnically-diverse areas. <i>British Journal of Cancer</i> , 2014, 111, 1440-1447.	2.9	34
167	Therapeutic Targeting of Integrin $\alpha 6$ in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	132
168	A telephone reminder intervention to improve breast screening information and access. <i>Public Health</i> , 2014, 128, 1017-1022.	1.4	15
169	An ongoing case-control study to evaluate the NHS Bowel Cancer Screening Programme. <i>BMC Cancer</i> , 2014, 14, 945.	1.1	1
170	A systematic review of the characteristics associated with recall rates, detection rates and positive predictive values of computed tomography screening for lung cancer. <i>Annals of Oncology</i> , 2014, 25, 781-791.	0.6	12
171	Trends in aggregate cancer incidence rates in relation to screening and possible overdiagnosis: A word of caution. <i>Journal of Medical Screening</i> , 2014, 21, 24-29.	1.1	13
172	Recent results from the two Canadian Breast Screening Trials. <i>Journal of Medical Screening</i> , 2014, 21, 59-60.	1.1	2
173	The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening. <i>Cancer Prevention Research</i> , 2014, 7, 362-371.	0.7	112
174	MRI breast screening in high-risk women: cancer detection and survival analysis. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 663-672.	1.1	133
175	MyLungRisk: a user-friendly, web-based calculator for risk assessment of lung cancer based on the validated Liverpool Lung Project risk prediction model. <i>International Journal of Health Promotion and Education</i> , 2014, 52, 144-152.	0.4	7
176	Breast cancer screening causes more harm than good: No. <i>Journal of Primary Health Care</i> , 2014, 6, 81-2.	0.2	0
177	Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time. <i>Breast Cancer Research</i> , 2013, 15, R41.	2.2	75
178	An ongoing case-control study to evaluate the NHS breast screening programme. <i>BMC Cancer</i> , 2013, 13, 596.	1.1	7
179	The contribution of risk prediction models to early detection of lung cancer. <i>Journal of Surgical Oncology</i> , 2013, 108, 304-311.	0.8	21
180	Reduction in rate of node metastases with breast screening: consistency of association with tumor size. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 653-663.	1.1	14

#	ARTICLE	IF	CITATIONS
181	A randomised trial of weekend and evening breast screening appointments. <i>British Journal of Cancer</i> , 2013, 109, 597-602.	2.9	16
182	Real and artificial controversies in breast cancer screening. <i>Breast Cancer Management</i> , 2013, 2, 519-528.	0.2	36
183	Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort study. <i>Health Technology Assessment</i> , 2013, 17, vii-xiv, 1-95.	1.3	11
184	The Impact of Mammographic Screening on Breast Cancer Mortality in Europe: A Review of Observational Studies. <i>Journal of Medical Screening</i> , 2012, 19, 14-25.	1.1	348
185	Overdiagnosis in Mammographic Screening for Breast Cancer in Europe: A Literature Review. <i>Journal of Medical Screening</i> , 2012, 19, 42-56.	1.1	338
186	Clinical and epidemiological issues in mammographic density. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 33-40.	12.5	98
187	Overdiagnosis in the population-based service screening programme with mammography for women aged 40 to 49 years in Sweden. <i>Journal of Medical Screening</i> , 2012, 19, 14-19.	1.1	208
188	Long-term benefits of breast screening. <i>Breast Cancer Management</i> , 2012, 1, 31-38.	0.2	27
189	Strategy for power calculation for interactions: Application to a trial of interventions to improve uptake of bowel cancer screening. <i>Contemporary Clinical Trials</i> , 2012, 33, 213-217.	0.8	6
190	UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. <i>Thorax</i> , 2011, 66, 308-313.	2.7	190
191	Potential surrogate endpoints in cancer research - some considerations and examples. <i>Pharmaceutical Statistics</i> , 2011, 10, 34-39.	0.7	3
192	Prognosis and pathology of screen-detected carcinomas. <i>Cancer</i> , 2011, 117, 1360-1368.	2.0	47
193	Effectiveness of population-based service screening with mammography for women ages 40 to 49 years. <i>Cancer</i> , 2011, 117, 714-722.	2.0	213
194	Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence. <i>Cancer Epidemiology</i> , 2011, 35, 139-144.	0.8	4
195	Swedish Two-County Trial: Impact of Mammographic Screening on Breast Cancer Mortality during 3 Decades. <i>Radiology</i> , 2011, 260, 658-663.	3.6	638
196	Comparison of discriminatory power and accuracy of three lung cancer risk models. <i>British Journal of Cancer</i> , 2010, 103, 423-429.	2.9	62
197	Effect of Baseline Breast Density on Breast Cancer Incidence, Stage, Mortality, and Screening Parameters: 25-Year Follow-up of a Swedish Mammographic Screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1219-1228.	1.1	155
198	Reply to Explaining variations in survival in breast cancer in the Eastern Region of England. <i>Annals of Oncology</i> , 2010, 21, 670.	0.6	0

#	ARTICLE	IF	CITATIONS
199	Absolute Numbers of Lives Saved and Overdiagnosis in Breast Cancer Screening, from a Randomized Trial and from the Breast Screening Programme in England. <i>Journal of Medical Screening</i> , 2010, 17, 25-30.	1.1	217
200	Modelling the likely effect of the increase of the upper age limit from 70 to 73 for breast screening in the UK National Programme. <i>Statistical Methods in Medical Research</i> , 2010, 19, 547-555.	0.7	3
201	Cancer mortality in the 50-69 year age group before and after screening. <i>Journal of Medical Screening</i> , 2010, 17, 159-160.	1.1	13
202	Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. <i>Lancet</i> , The, 2010, 375, 1624-1633.	6.3	1,483
203	Commentary on 'What is the point: will screening mammography save my life?' by Keen and Keen. <i>BMC Medical Informatics and Decision Making</i> , 2009, 9, 19.	1.5	0
204	Reply: Estimation of lead-time and overdiagnosis in breast cancer screening. <i>British Journal of Cancer</i> , 2009, 100, 220-220.	2.9	2
205	Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. <i>British Journal of Cancer</i> , 2009, 101, 1338-1344.	2.9	77
206	Early detection of second breast cancers improves prognosis in breast cancer survivors. <i>Annals of Oncology</i> , 2009, 20, 1505-1510.	0.6	154
207	Use of lung cancer risk models in planning research and service programs in CT screening for lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1467-1472.	1.1	9
208	A case-control study of the impact of the East Anglian breast screening programme on breast cancer mortality. <i>British Journal of Cancer</i> , 2008, 98, 206-209.	2.9	62
209	The LLP risk model: an individual risk prediction model for lung cancer. <i>British Journal of Cancer</i> , 2008, 98, 270-276.	2.9	406
210	Reply: Early onset of breast cancer in British black women. <i>British Journal of Cancer</i> , 2008, 98, 2012-2012.	2.9	3
211	Lung cancer screening: the way forward. <i>British Journal of Cancer</i> , 2008, 99, 557-562.	2.9	50
212	Reply: Early onset of breast cancer in black British women: how reliable are the findings?. <i>British Journal of Cancer</i> , 2008, 99, 988-988.	2.9	1
213	Complexities in the estimation of overdiagnosis in breast cancer screening. <i>British Journal of Cancer</i> , 2008, 99, 1176-1178.	2.9	69
214	Visually assessed breast density, breast cancer risk and the importance of the craniocaudal view. <i>Breast Cancer Research</i> , 2008, 10, R64.	2.2	44
215	Screening opportunity bias in case-control studies of cancer screening. <i>Journal of Applied Statistics</i> , 2008, 35, 537-546.	0.6	8
216	A case-control study to estimate the impact of the icelandic population-based mammography screening program on breast cancer death. <i>Acta Radiologica</i> , 2007, 48, 948-955.	0.5	55

#	ARTICLE	IF	CITATIONS
217	Avoiding bias from aggregate measures of exposure. <i>Journal of Epidemiology and Community Health</i> , 2007, 61, 461-463.	2.0	5
218	Screening younger women with a family history of breast cancer – does early detection improve outcome?. <i>European Journal of Cancer</i> , 2006, 42, 1385-1390.	1.3	42
219	Tumor Size and Breast Cancer Detection: What Might Be the Effect of a Less Sensitive Screening Tool Than Mammography?. <i>Breast Journal</i> , 2006, 12, S91-S95.	0.4	34
220	Overdiagnosis, Sojourn Time, and Sensitivity in the Copenhagen Mammography Screening Program. <i>Breast Journal</i> , 2006, 12, 338-342.	0.4	86
221	Family history and risk of lung cancer: age-at-diagnosis in cases and first-degree relatives. <i>British Journal of Cancer</i> , 2006, 95, 1288-1290.	2.9	27
222	Some issues in screening for breast and other cancers. <i>Journal of Medical Screening</i> , 2006, 13 Suppl 1, S28-34.	1.1	0
223	Modelling and analysis of DCIS detection and reduction in invasive carcinoma – a review. <i>Breast Cancer Online: BCO</i> , 2005, 8, .	0.1	0
224	A review of cancer screening evaluation techniques, with some particular examples in breast cancer screening. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2005, 168, 657-677.	0.6	9
225	What should the detection rates of cancers be in breast screening programmes?. <i>British Journal of Cancer</i> , 2005, 92, 597-600.	2.9	16
226	Some current issues in breast cancer screening. <i>Journal of Medical Screening</i> , 2005, 12, 128-133.	1.1	15
227	Screening for Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2005, 14, 671-697.	0.6	23
228	Overdiagnosis and overtreatment of breast cancer: Overdiagnosis and overtreatment in service screening. <i>Breast Cancer Research</i> , 2005, 7, 266-70.	2.2	49
229	Overdiagnosis and overtreatment of breast cancer: Estimates of overdiagnosis from two trials of mammographic screening for breast cancer. <i>Breast Cancer Research</i> , 2005, 7, 258-65.	2.2	150
230	Overdiagnosis in Screening: Is the Increase in Breast Cancer Incidence Rates a Cause for Concern ?. <i>Journal of Medical Screening</i> , 2004, 11, 23-27.	1.1	80
231	Modelling the impact of detecting and treating ductal carcinoma in situ in a breast screening programme. <i>Journal of Medical Screening</i> , 2004, 11, 117-125.	1.1	28
232	A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales. <i>Journal of Medical Screening</i> , 2004, 11, 194-198.	1.1	47
233	Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern?. <i>Journal of Medical Screening</i> , 2004, 11, 23-27.	1.1	79
234	A simple model for potential use with a misclassified binary outcome in epidemiology. <i>Journal of Epidemiology and Community Health</i> , 2004, 58, 712-717.	2.0	30

#	ARTICLE	IF	CITATIONS
235	Interaction of dense breast patterns with other breast cancer risk factors in a case-control study. <i>British Journal of Cancer</i> , 2004, 91, 233-236.	2.9	23
236	A breast cancer prediction model incorporating familial and personal risk factors. <i>Statistics in Medicine</i> , 2004, 23, 1111-1130.	0.8	1,052
237	Mammographic tumor features can predict long-term outcomes reliably in women with 14-mm invasive breast carcinoma. <i>Cancer</i> , 2004, 101, 1745-1759.	2.0	208
238	The randomized trials of breast cancer screening: what have we learned?. <i>Radiologic Clinics of North America</i> , 2004, 42, 793-806.	0.9	316
239	The Gothenburg Breast Screening Trial. <i>Cancer</i> , 2003, 97, 2387-2396.	2.0	216
240	Misclassification in a matched case-control study with variable matching ratio: application to a study of c-erbB-2 overexpression and breast cancer. <i>Statistics in Medicine</i> , 2003, 22, 2459-2468.	0.8	9
241	Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. <i>European Journal of Cancer</i> , 2003, 39, 1746-1754.	1.3	131
242	Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. <i>Lancet, The</i> , 2003, 361, 1405-1410.	6.3	611
243	The relative contributions of screen-detected in situ and invasive breast carcinomas in reducing mortality from the disease. <i>European Journal of Cancer</i> , 2003, 39, 1755-1760.	1.3	85
244	Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. <i>British Journal of Cancer</i> , 2002, 86, 218-221.	2.9	30
245	All-cause mortality among breast cancer patients in a screening trial: support for breast cancer mortality as an end point. <i>Journal of Medical Screening</i> , 2002, 9, 159-162.	1.1	71
246	The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. <i>Cancer</i> , 2002, 95, 458-469.	2.0	364
247	Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2002, 51, 235-243.	0.5	70
248	Beyond randomized controlled trials. <i>Cancer</i> , 2001, 91, 1724-1731.	2.0	513
249	Interpretation of the breast screening trials: a commentary on the recent paper by Gtzsche and Olsen. <i>Breast</i> , 2001, 10, 209-212.	0.9	49
250	A novel method for prediction of long-term outcome of women with T1a, T1b, and 10-14 mm invasive breast cancers: a prospective study. <i>Lancet, The</i> , 2000, 355, 429-433.	6.3	129
251	THE SWEDISH TWO-COUNTY TRIAL TWENTY YEARS LATER. <i>Radiologic Clinics of North America</i> , 2000, 38, 625-651.	0.9	409
252	Primary and Adjuvant Therapy, Prognostic Factors and Survival in 1053 Breast Cancers Diagnosed in a Trial of Mammography Screening. <i>Japanese Journal of Clinical Oncology</i> , 1999, 29, 608-616.	0.6	30

#	ARTICLE	IF	CITATIONS
253	A mover-stayer mixture of Markov chain models for the assessment of dedifferentiation and tumour progression in breast cancer. <i>Journal of Applied Statistics</i> , 1997, 24, 265-278.	0.6	18
254	The Gothenburg Breast Cancer Screening Trial: Preliminary Results on Breast Cancer Mortality for Women Aged 39-49. <i>Journal of the National Cancer Institute Monographs</i> , 1997, 1997, 53-55.	0.9	67
255	Recent Results From the Swedish Two-County Trial: The Effects of Age, Histologic Type, and Mode of Detection on the Efficacy of Breast Cancer Screening. <i>Journal of the National Cancer Institute Monographs</i> , 1997, 1997, 43-47.	0.9	56
256	Markov Models of Breast Tumor Progression: Some Age-Specific Results. <i>Journal of the National Cancer Institute Monographs</i> , 1997, 1997, 93-97.	0.9	93
257	The Gothenburg breast screening trial. , 1997, 80, 2091-2099.		195
258	Efficacy of breast cancer screening by age. New results swedish two-county trial. <i>Cancer</i> , 1995, 75, 2507-2517.	2.0	526
259	Screening for Breast Cancer in Women Aged under 50: Mode of Detection, Incidence, Fatality, and Histology. <i>Journal of Medical Screening</i> , 1995, 2, 94-98.	1.1	46
260	Development of a scoring system to judge the scientific quality of information from case-control and cohort studies of nutrition and disease. <i>Nutrition and Cancer</i> , 1995, 24, 231-239.	0.9	34
261	Update of the Swedish two-county program of mammographic screening for breast cancer. <i>Radiologic Clinics of North America</i> , 1992, 30, 187-210.	0.9	185
262	Breast screening, prognostic factors and survival " results from the Swedish two county study. <i>British Journal of Cancer</i> , 1991, 64, 1133-1138.	2.9	166
263	The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit.. <i>Journal of Epidemiology and Community Health</i> , 1989, 43, 107-114.	2.0	322
264	Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 959-962.	0.9	61